No Detail Found!

Exenatide Implant Therapy in Diabetes.

Author(s)
Sanjay Kalra Department of Endocrinology, Bharti Hospital, Karnal,
Banshi Saboo Department of Diabetology, DiaCare, Ahmedabad, India
Abstract
This review describes a recent advance in diabetes pharmacotherapeutics and drug delivery. ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exenatide, when inserted subcutaneously. The article discusses the pharmacodynamics and pharmacokinetics of ITCA 650, and suggests how it's benefits can be utilized in clinical practice. It lists the advantages and limitations of the device, and shares tips for its rational use in type 2 diabetes care.
Publication Details
Page(s) 1538-1540
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 68, Issue: 10, Year: 2018

Request the full text from PASTIC

References
KalraS., 2013.Glucagon-like peptide-1 receptors agonists (GLP1 RA),J Pak Med Assoc 63 1312 -5
IntarciaAnnounces, 2017.Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results,Cited on 30 October -
Delpor, 2017.Awarded $1.5 million NIH Grant for Exenatide Implant for the Treatment of Type 2 Diabetes,id=1028. Cited on 30 October -
2017.Current drug delivery limitations,Cited on 30 October -
Applications, 2017.,Cited on 30 October -
TheMedici Drug Delivery System, 2017.,Cited on 30 October -
HenryRR,LoganD,AlessiT,BaronMA, .A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes., -
2013.Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes,Diabetes care 36 2559 -65
2014.Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes,J Diabetes Complications 28 393 -8
HenryR,RosenstockJ,McCarthyJF,CarlsG,AlessiT,YeeJ,BaronM, 2018.Treatment Satisfaction with ITCA 650, a Novel Drug?device Delivering Continuous Exenatide versus Twice?Daily Injections of Exenatide in Type 2 Diabetics on Metformin,Diabetes Obes Metab 10 638 -645
0

Citations

0

Downloads

70

Views